RIGL at a glance
RIGEL PHARMACEUTICALS INC (RIGL, SEC CIK 1034842) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), RIGEL PHARMACEUTICALS INC (RIGL) reported revenue of $294.3 million (up 64.1% from FY2024) and net income of $367.0 million. Diluted EPS was $19.48.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $294.3M
- +64.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New VEPPANU transition risk, triggered by June 11, 2026 license effectiveness and August 13 launch, includes $40.0 million development funding cap
- Most material operational update: Pfizer supply agreement carries $24.8 million estimated minimum-purchase obligation through 2030
- Regulatory risk: CMS’s GLOBE Model final rule starts April 1, 2027, requiring rebates tied to international drug prices
- Competitive risk: Annora’s generic fostamatinib approved June 2026, with sales licensed to begin second quarter 2032
- Financial risk: MidCap revolving facility had $8.0 million outstanding at September 30, 2026, with variable SOFR-based interest
Management Discussion & Analysis
- Quarterly revenue $80.9M, up $11.4M YoY from $69.5M
- Product sales $72.3M, up $8.2M YoY, led by TAVALISSE at $46.0M
- Best performer: REZLIDHIA $9.9M, up 20% YoY; worst: GAVRETO $9.8M, down 11%
- Operating cash flow $67.9M through nine months, versus $53.7M YoY; cash and investments $99.3M
- Outlook: product sales expected to increase with VEPPANU launch, offset by rebate, reimbursement and competitive risks
AI summary of the RIGL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Rigel announced financial results for Q3 2026, ended September 30, 2026
- Investor-relevant figures and management commentary are contained in Exhibit 99.1, “Rigel Reports Third Quarter 2026 Financial Results”
Item EX-99.1: Item EX-99.1
- Q3 revenue $80.9M, up from $69.5M, driven by product sales growth and $8.6M collaboration revenue
- VEPPANU launched August 13, generating $6.6M initial sales and becoming the key commercial growth catalyst
Item EX-99.1: Item EX-99.1
- Q2 revenue $78.7M, with product sales $67.0M up 14%; TAVALISSE led growth at $47.4M, up 18%
- Net income $17.3M versus $59.6M, reflecting prior-year $40.0M non-cash Lilly collaboration revenue
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Investor-relevant figures and management commentary contained in Exhibit 99.1 press release
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Alison L. Hannah appointed Executive Vice President and Chief Medical Officer effective July 1, 2026
- Hannah resigned from Rigel’s Board upon appointment, ending service that began in May 2021
AI summaries of RIGL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RIGL
Don't miss the next RIGL filing
- Alerts as it files. A push when RIGL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RIGL, by share count.
- Ask anything. An AI agent that reads every RIGL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Schorno Dean L | M | Sep 2, 2026 | 620 | $18.70 |
| Schorno Dean L | M | Sep 2, 2026 | 2,000 | - |
| Schorno Dean L | M | Sep 2, 2026 | 1,286 | - |
| Schorno Dean L | M | Sep 2, 2026 | 2,000 | $24.20 |
| Schorno Dean L | M | Sep 2, 2026 | 620 | - |
| Schorno Dean L | M | Sep 2, 2026 | 694 | - |
| Schorno Dean L | M | Sep 2, 2026 | 694 | $12.70 |
| Schorno Dean L | M | Sep 2, 2026 | 1,286 | $24.20 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $116.9M | $179.3M | $294.3M |
| Operating Income | - | $24.2M | $125.5M |
| Net Income | -$25.1M | $17.5M | $367.0M |
| Op. Margin | - | 13.5% | 42.6% |
| Net Margin | -21.5% | 9.8% | 124.7% |
| Balance Sheet | |||
| Total Assets | $117.2M | $164.0M | $513.6M |
| Equity | -$28.6M | $3.3M | $391.5M |
| ROE | 87.6% | 531.8% | 93.8% |
| Per Share | |||
| EPS | $-0.14 | $0.99 | $19.48 |
| Cash Flow | |||
| Operating CF | -$5.7M | $31.5M | $75.7M |
Source: XBRL data in RIGEL PHARMACEUTICALS INC (RIGL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
RIGL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jul 10, 2026 | - | - | - |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 17, 2026 | - | Analysis | - |
| 4 | May 28, 2026 | - | - | |
| 8-K | May 20, 2026 | - | Analysis | |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 12, 2026 | - | Analysis | |
| SC 13G | May 7, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 21, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
RIGL SEC filings: frequently asked questions
What was RIGL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), RIGEL PHARMACEUTICALS INC (RIGL) reported revenue of $294.3 million (up 64.1% from FY2024) and net income of $367.0 million. Diluted EPS was $19.48. The figures come from the XBRL data in the 10-K.
What did RIGL report in its latest 8-K?
RIGEL PHARMACEUTICALS INC (RIGL) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Rigel announced financial results for Q3 2026, ended September 30, 2026.
What are the latest RIGL SEC filings?
RIGEL PHARMACEUTICALS INC (RIGL) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on September 3, 2026.
What is RIGL's SEC CIK number?
RIGEL PHARMACEUTICALS INC (RIGL)'s SEC Central Index Key (CIK) is 1034842. EDGAR lists every RIGL filing under that number.
Ask anything about RIGL
The research agent reads RIGL's filings, financials, insider trades and 13F holders, then answers with sources.